Toragen, Inc. Announces Chief Medical Officer to Drive the Company’s Clinical Development

Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)

SAN DIEGO--(BUSINESS WIRE)--Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing, and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), today announced that Neil Clendeninn, MD, PhD, joined as Chief Medical Officer.

Dr. Clendeninn has worked for over 20 years in the pharmaceutical and biotechnology industry and has an established track record of successful drug development. Most recently Dr. Clendeninn served as the Senior Vice President and Chief Medical Officer of Heron Therapeutics, in San Diego, CA, where he established the clinical departments including Medical Affairs, Clinical Operations, Clinical Research and Biostatistics. He was instrumental in gaining the approval of SUSTOL, a long-acting granisetron formulation for chemotherapy-induced nausea and vomiting. Previously he held the position of Vice President of Clinical Affairs for Agouron Pharmaceuticals, of La Jolla, CA where he helped develop the anti-viral HIV protease inhibitor Viracept (Nelfinavir).

“We are thrilled to welcome Dr. Clendeninn to the Toragen team at such a critical time in our corporate growth,” said Dr. Sandra Coufal, Toragen’s CEO. “Dr. Clendininn’s direct experience in clinical oncology, and his long career in drug development, including anti-virals, is an ideal match for Toragen, and I look forward to his leadership of our Phase I clinical trial.”

About Toragen

Toragen, a pre-clinical stage biotechnology company, is targeting the root cause of virally induced cancers. https://toragen.com.